Volitionrx Limited (VNRX) Reports Q1 Loss of $0.12/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Ovintiv adds 41,000 acres in Permian and Montney deals
- Russia says it could strike UK military targets in response to Kyiv's use of British missiles
VolitionRx Announces First Quarter 2015 Financial Results and Business Update
May 12, 2015 7:50 AM EDTNAMUR, Belgium, May 12, 2015 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced financial results for the first quarter ended March 31, 2015.Â
First Quarter 2015 and Recent Company Highlights:
Completed NYSE MKT listing in conjunction with $10.6 million fully registered offering of common shares, plus an additional $1.5 million received in funding from a Private Placement in March... More